Pelacarsen (TQJ230) 80mg + Matching placebo
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Stenosis
Conditions
Aortic Stenosis
Trial Timeline
Mar 7, 2024 → Mar 12, 2030
NCT ID
NCT05646381About Pelacarsen (TQJ230) 80mg + Matching placebo
Pelacarsen (TQJ230) 80mg + Matching placebo is a phase 2 stage product being developed by Novartis for Aortic Stenosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05646381. Target conditions include Aortic Stenosis.
What happened to similar drugs?
6 of 14 similar drugs in Aortic Stenosis were approved
Approved (6) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05646381 | Phase 2 | Recruiting |
Competing Products
20 competing products in Aortic Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 26 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 36 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 43 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 35 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 40 |
| candesartan + placebo | AstraZeneca | Phase 3 | 36 |
| Sugammadex | Merck | Approved | 43 |
| bisoprolol + placebo | Merck | Approved | 35 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 42 |
| fluvastatin | Novartis | Phase 2 | 31 |
| ACZ885 + Placebo | Novartis | Phase 2 | 27 |
| Evolocumab + Placebo | Amgen | Phase 1 | 36 |
| atorvastatin (Lipitor) | Pfizer | Approved | 35 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 40 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 29 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 35 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 35 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 29 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 37 |
| Desflurane | Baxter | Approved | 36 |